⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
SNY News
Sanofi American Depositary Shares (Each representing one-half of one ordinary share)
Hyperphosphatemia Market Set for Robust Growth During the Forecast Period (2026-2036), Driven by Novel Therapeutics and Rising CKD Burden | DelveInsight
prnewswire.com
SNY
TailorMed and RxSense Partner to Surface Manufacturer Copay Assistance Within Digital Pharmacy Marketplaces
accessnewswire.com
BMY
SNY
MRK
LLY
Press Release: Sanofi’s MenQuadfi approved in the EU for use in infants from age six weeks against invasive meningococcal disease
globenewswire.com
SNY
Peripheral Artery Disease Clinical Trial Pipeline Expands as 17+ Companies Race to Redefine Peripheral Artery Disease Treatment Landscape | DelveInsight
globenewswire.com
CLRS
MDT
PHG
BSX
BDX
BIOT
ABT
ANGI
RMAX
MRK
SNY
JNJ
BA
GSK
AZN
PFE
NVO
AMGN
VRTX
Press Release: Sanofi’s half-year financial report for 2026
globenewswire.com
SNY
Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded
globenewswire.com
SNY
Amylin Analogs and Combination Therapies Clinical Trial Landscape Expands as 15+ Leading Companies Accelerate Drug Development | DelveInsight
globenewswire.com
AZN
LLY
NVO
PFE
AMGN
BMY
JNJ
REGN
VKTX
ZETA
CRSP
IONS
AXSM
MRK
GSK
SNY
IMUX
BMEA
ALKS
ALT
AARD
NOV
CARM
CRIS
LPCN
GILD
REG
SPRO
ABSI
ALZN
ANVS
BV
ARCL
ACIU
Press Release: Sanofi announces decision not to submit amlitelimab in atopic dermatitis for global regulatory reviews
globenewswire.com
SNY
Scribe Therapeutics Announces Pricing of Upsized Initial Public Offering
globenewswire.com
SNY
LLY
ALK Inhibitors Market Set for Transformational Growth at a CAGR of 4% During the Forecast Period (2026-2036) Backed by Next-Generation Targeted Therapies| DelveInsight
prnewswire.com
PFE
MRK
LLY
AMGN
BMY
NVS
GILD
AZN
REGN
SNY
TEVA
IMUX